A guide for primary care providers Opioid Stewardship & Chronic Pain



Letter to Readers

As part of our commitment to patient care and quality and due to Southern Illinois having higher rates of patient opioid prescriptions, SIH has been examining and improving practices and policies related to pain assessment, pain management and safe opioid prescribing and use. This Guide for Primary Care Providers on Opioid Stewardship and Chronic Pain, will provide information on CDC prescribing guidelines, pain management options and assessment, and information about substance misuse treatment and medication. We want to thank all of our physicians and advance practice providers for their care for patients throughout the Southern Illinois region. The SIH Pain Management Team will continue to provide support and education to our staff in order to provide consistent, quality care to our patients.

mimore-Quelly "D


Marci Moore-Connelley, MD, MBA Senior Vice President & Chief Medical Officer

Table of Contents


- » Overview and background 2
- » Assessments 8
- » Informed consent 12
- » When prescribing opioids 14
- » Illinois PMP 16
- » Naloxone 18
- » Opioid Use Disorder Management 24
- » Non-pharmaceutical options for pain management 30
- » References 32

46 people die every day from overdoses involving prescription opioids. In 2017, prescription opioids contributed to the U.S. epidemic as they were involved in more than 35% of all opioid overdose deaths.¹

Source: https://www.cdc.gov/drugoverdose/data/prescribing.html



Overdose is the leading cause of injury-related death in the US



Overdose deaths involving opioids, by type of opioid, United States, 2000–2016²

Any Opioid

Natural & Semi-Synthetic Opioids (e.g., oxycodone, hydrocodone)

Heroin

Methadone

Other Synthetic Opioids (e.g., fentanyl, tramadol) Opioids—mainly synthetic opioids (other than methadone)—are currently the main driver of drug overdose deaths. Opioids were involved in 47,600 overdose deaths in 2017 (67.8% of all drug overdose deaths).³

Source: https://www.cdc.gov/drugoverdose/data/statedeaths.html

In 2017, there were 70,237 drug overdose deaths in the United States. $^{\rm 4}$

Source: https://www.cdc.gov/nchs/data/databriefs/db329-h.pdf

Among persons aged 15 and over, adults aged 25–34, 35–44, and 45–54 had the highest rates of drug overdose deaths in 2016.²


Source: https://www.cdc.gov/nchs/data/databriefs/db294.pdf

The rate of drug overdose deaths involving synthetic opioids other than methadone doubled in a single year. $^{\rm 2}$

Source: https://www.cdc.gov/nchs/data/databriefs/db294.pdf

Overview and background

Opioid overdose deaths in Illinois



High risk patient populations



0.54

23.45

Accidental opioid overdose is preventable

Prior opioid overdose is a major risk for subsequent overdose and overdose death. A patient who has previously overdosed is **6 times more likely to overdose** in the subsequent year.⁶

Other factors that increase risk of overdose:

Reduced tolerance: period of abstinence, change in dose, release from incarceration Genetic predisposition

Concomitant use of substances: benzodiazepines, alcohol, cocaine

The majority of opioid overdose deaths involve at least one other drug, including benzodiazepines, cocaine or alcohol.⁷

Managing chronic non-cancer pain

Movement-based therapies

Physical/occupational therapy Supervised/graded physical activity

Medication

NSAID/Acetaminophen Anticonvulsants Antidepressants Topical (lidocaine, capsacin) Immune modulators Muscle relaxants Buprenorphine Lowest effective opioid dose

Integrative therapies

Massage, counterstrain Chiropracty, acupuncture Supplements, anti-inflammatory eating Yoga, Tai Chi Mindfulness

Behavioral therapies

Individual therapy Depression/anxiety group Health/pain group Social engagement plan Cognitive Behavioral Therapy (CBT)

Procedures

Injections (joint, trigger point, epidural) Referrals (orthopedics, neurosurgery, pain clinic)


Ice/heat

If opioid medication is part of the treatment plan, take the following steps:

- » Assessments of risk, adherence, function and pain: at least annually
- » Informed consent or pain agreement: at least annually
- » Prescription drug monitoring program: check Illinois Prescription Monitoring Program every 4 months
- » Prescribe Naloxone: every two years

If managing opioid use disorder, options include:

- » Prescribe buprenorphine
- » Arrange for methadone maintenance or extended-release naltrexone
- » Arrange for residential or outpatient treatment



Assessments

Pain and function assessments

Assessments should focus on both pain and function.

- » Assessments are essential when initiating opioid treatment or seeing a new patient already on long-term opioid therapy.
- » Reassessments should take place at regular intervals to ensure benefit and evaluate adverse events.

CDC Recommends

Assessments should take place within three months of starting treatment and at least annually thereafter.


SIH Policies

» For more information on pain and function assessments see the following SIH policy:

Pain Assessment & Management SY-NG-021

Tools

There are several tools for assessing pain and function such as the "Wong-Baker FACES Pain Rating Scale", which is one of the rating scales used at SIH.



Risk factor assessment

Once you have determined that opioids are indicated for a patient, assessing for risk factors may help guide therapeutic decisions.

Assessing for risk of an opioid use disorder can be done with simple questions like:

"How many times in the past year have you used an illegal drug or used a prescription medication for non-medical reasons?" ⁹

In a primary care setting (with an answer of one or more considered positive) this question was 100% sensitive and 73.5% specific in detecting a substance use disorder compared with a standardized diagnostic screening.

When assessing for safety with opioid therapy, consider:

- » Concomitant medications (particularly benzodiazepines)
- » Comorbidities that can affect respiration (e.g. sleep apnea, tobacco or alcohol use disorder)
- » History of prior overdose or similar adverse reaction to opioids
- » Total daily dose of opioids

The presence of risk factors does not necessarily contraindicate opioid therapy, but can be used to emphasize alternatives, limit dose and intensify monitoring.

Assessments

Urine drug screening

Urine drug screening can be used to check for substances that are expected and not expected to be present. This can help guide an informed discussion with patients about their medications.

- » Urine drug screening should NOT be used as a punitive tool, rather it should be used like hemoglobin A1C, as a guide to ensure optimal care.
- » Urine drug testing should be done more frequently for patients at higher risk.

Contact your lab for assistance interpreting urine drug screening results

Tests and interpretations can vary by lab. Reach out to your local lab when you need help interpreting results.

- **» Not all assays test for all substances**. Opioids like methadone, fentanyl and buprenorphine may not appear on all tests.
- » Some opioids may be metabolites of opioids a patient is prescribed. For example, the presence of hydromorphone in the urine of a patient prescribed morphine may be due to metabolism rather than use of non-prescribed opioids.

Opioid metabolic pathways

 Morphine
 Heroin
 Codeine

 Hydromorphone
 Hydrocodone

 Oxycodone
 Oxymorphone

CDC Recommends

Conduct urine drug screening at first opioid prescription and at least annually thereafter.





Informed consent

Informed consent and treatment agreements

- Informed Consent is a joint discussion between provider and patient, documented in the chart, addressing risks associated with opioids and clarifying expectations.
- Treatment agreements are written documents, similar to and possibly replacing informed consent, that address risks of opioid therapies, as well as expectations of both the patient and provider. Pain agreements are generally signed by the patient and renewed annually.

At a minimum, providers should offer written information to patients about the benefits and risks of opioid therapy and document patients' understanding and agreement when initiating long-term opioid therapy and **at least annually** thereafter.

CDC Recommends

Review informed consent or treatment agreements at least annually.

7/9/2019 htrolled Substance Agreement purpose of this agreement is to set out the rules that patients must follow in order for this office to cribe medications that are controlled by the Drug Enforcement Agency (DEA). These rules are meant to re that such medications are prescribed in a safe and responsible manner. Failure to follow the rules does mean the patient is necessarily abusing medications, but it does mean that this office may not be able to cribe any more controlled medications for the patient. These rules apply to all patients who receive rolled medications from this office on an ongoing basis. By initialing each line of the agreement below, I, the	//9/201 /
ersigned patient, acknowledge that I have read and understand each rule. 1) I will not obtain controlled substances from any other source without informing this office. For instance, if I receive a prescription for painkillers from a dentist or an emergency room, I am to inform this office at the first available opportunity. Controlled Medications from other providers include:	end, I am to arrive at my appointments ready and able to provide a urine sample. If I feel the need to empty my bladder before being seen, I am to ask the staff if I will need to provide urine for a dru screen. 14) If requested, I agree to come in with my prescription medications for a pill count within two days. 15) I agree to use only the designated pharmacy listed on this Agreement for my controlled medications. Pharmacy Name:
2) I am not allowed to "try", "borrow", or otherwise use medications from a relative, friend, or other source.	16) I understand that I might be required to pick up my prescriptions every month in person from the office.
3) I will not take any old or "left over" medications, whether prescribed by this office or a previous office.	17) I understand that alcohol should be avoided with the medications that I am prescribed. 18) If I discontinue using a prescribed controlled substance, I will dispose of any controlled substances
I must inform the office if I do not need to take my medications on a regular basis. If my drug screen does not show medications that I am supposed to be taking, it might mean that this office will no longer provide me with this medication. I am not allowed to sell, trade, or share my medication with anyone, including spouses and other	myself by taking to a designated drop-off center. 19) I am not to refill prescriptions from any previous physician(s) without informing this office. 20) I will not drive or operate heavy machinery if I sense any side effects of these medications. It is my responsibility to ensure I do not endanger myself or anyone else while taking these medications.
family members. 7) I am not to use illegal substances.	Patient Printed Name: DOB: DOB:
8) I am not to increase my medication dosage without permission from this office. For example, I am prescribed painkillers to take up to three times a day; I am not permitted to increase this dose by myself. If I experience a flare up of pain, I must contact this office to get permission to increase my dose.	Patient Signature: Date: Time: Parent/Guardian Signature (if under 18): Date: Time:
 9) I will not consume anything with poppy seeds as it can interfere with drug screens. 10) I understand that controlled medications have street value and must be safeguarded. I am responsible for any medications prescribed to me. I understand that lost or stolen medication will NOT be replaced. 	Witnessed by: (Print Name) Witness signature:Date:

There are pain agreement templates available online. See SIH Resource section for more info.

Informed consent

What to include in a treatment agreement

Essential

- » Reason for treatment
- » Potential benefits and risks
- » Assessments
- » Expectations for future visits
- » Discontinuation plan

Optional

- » Additional elements of treatment plan (medication, other non-opioid treatments, physical therapy, etc.)
- » Therapeutic goals, including physical ability, social function, dosing, duration
- » Requirements for external consultation

Unused medications?

Unused medications can be disposed of at the following SIH locations

SIH Memorial Hospital of Carbondale 405 W. Jackson St. | Carbondale, IL 62902 Mon – Fri: 7:30 am – 6:00 pm | Sat – Sun: 7:30 am – 6:00 pm

SIH Herrin Hospital 201 S. 14th St. | Herrin, IL 62948 Mon – Fri: 7:30 am – 6:00 pm | Sat – Sun: 7:30 am – 6:00 pm

SIH St. Joseph Memorial Hospital

2 S. Hospital Dr. | Murphysboro, IL 62966 Mon – Fri: 6:00 am – 4:30 pm | Sat – Sun: 7:00 am – 2:30 pm

SIH Cancer Institute

1400 Pin Oak Dr. | Carterville, IL 62918 Mon – Fri: 7:30 am – 3:30 pm | Sat – Sun: CLOSED



Additional considerations

Patient engagement

- » Remind patients to keep opioids in a locked and safe place.
- » Encourage safe disposal of drugs.
- » SIH has drug disposal units for the public at all three SIH hospitals and the SIH Cancer Institute. Take back events are also held periodically in the community.

When prescribing opioids

Starting opioid therapy

CDC Recommends

Consider using episodic short-acting opioids and keeping at lowest effective dose.



Exercise caution

- » Doses ≥ 50 MME
- » Concurrent use of benzodiazepine, alcohol or methadone for pain



Avoid if possible » Doses ≥ 90 MME

Inheriting patients already on opioid therapy can be complex

- » Discuss with former provider
- » Complete baseline assessments
- » Establish expectations
- » Engage in opioid use disorder treatment if appropriate



67% of those prescribed opioids for 90 days are still using opioids at 2 years.¹⁰

Tapering or discontinuing opioids

When to taper

» When risks outweigh benefits

Consider tapering when opioid dose ≥90 MME or patient also takes benzodiazepines.

How to taper

- » 1 medication at a time
- » Tapers usually involve a monthly reduction of 10% of original dose
- » Tapers may be as rapid as 50% in situations such as a low original dose or life-threatening adverse events

Consider a partial taper or transition to buprenorphine for some patients, particularly those on years of opioid therapy.

"I am more alert since I stopped taking [opioids] and I need less sleep, which is a blessing. So I'm able to do more things with my life."

- Patient formerly prescribed opioids for pain

CDC Recommends


Patient engagement

- » Individualize the plan and be prepared to adjust
- » Work with patient to set realistic goals
- » Remind patient that reducing opioid use may reduce sensitivity to pain
- » Encourage patient to engage support networks
- » Use motivational interviewing techniques



POCKET GUIDE: TAPERING OPIOIDS FOR CHRONIC PAIN

Follow up regularly with patients to determine whether opioids are meeting treatment goals and whether opioids can be reduced to lower dosage or discontinued.



Go to this link for a CDC patient toolkit on tapering:

tinyurl.com/hfr7drd

Illinois PMP

Illinois Prescription Monitoring Program (IL PMP)

Illinois' Prescription Monitoring Program (IL PMP) is an online system used by prescribers to review prescriptions of controlled substances.

- » The PMP is a database which collects information on controlled substance prescriptions dispensed by retail pharmacies in Illinois.
- » Public Act 100-0564 required prescribers with a controlled substance license to register on the PMP.
- Prescribers or designee shall document in the patient electronic health records (EHR) an attempt to access the PMP to assess patient access to controlled substances upon an initial prescription (each prescription is considered an initial prescription).

What information is provided by the PMP?

» Schedules II – V controlled substances prescriptions are viewable for 12 months and archived for two years.

Who can access the ilpmp.org site?

- » Physicians
- » Pharmacists
- » Dentists
- » Veterinarians
- » Physician Assistants and Advanced Practice Nurses
- » Other prescribers and dispensers

High quality prescription drug monitoring programs with mandated use may be associated with reduced opioid prescribing¹¹ and modest reductions in opioid analgesic deaths.¹²

> All retail pharmacies that dispense schedule drugs are required to report their prescription to the IL PMP on a daily basis. The prescriptions are then collected and updated on the IL PMP website each business day.

How to register for the Illinois Prescription Monitoring Program

How do I register for the PMP?

- 1. Go to www.ilpmp.org.
- 2. Watch "How to" video found under the Help & FAQ tab.
- 3. Go to the home page and click onto the Prescriber Link on the left side.
- 4. Fill out registration form and submit.
- 5. PMP will contact you with your user name (log in ID).
- 6. Insert user name, password, and security code . (Note: user name is not case sensitive, the remainder are)

There is a contact phone number listed if difficulties arise.

IL PMP Legislation

SB772 amends the Illinois Controlled Substances Act and has been effective since January 1, 2018, imposing several obligations on prescribers.

- » First, all prescribers who hold an Illinois Controlled Substances license must register with the PMP. Click here to register.
- » Next, before giving a patient a new prescription for a Schedule II narcotic prescribers or their designee must attempt to access the patient's information in the PMP and assess the patient's controlled substance history. Prescriptions for oncology treatment or palliative care, or for a 7-day or less supply provided by a hospital emergency department for an acute, traumatic medical condition, are exempt from the requirement. Prescribers must document the attempt to access the PMP in the patient's medical record.


Medications from IL PMP pull into the patient's chart in Epic. Workflows have been developed for ambulatory, inpatient and ASAP that will allow the providers to review IL PMP within Epic and document the review in their note in an efficient manner.

PC	MP Info									Ŕ
s	herlock Holmes									(MR # 9001988
Ne	dication Dispense Information	n (as of 1/18/2	2018)						Expan	d All Collapse /
	OXYCODONE HCL/ACETAMIN	NOPHEN								
	OXYCODONE/ACETAMIN		Written 08/19/2017	Strength 10MG- 325MG	Form	Quantity 5	Refills	Days Supply 30	Provider , WATSON, MICHAEL JAMES MD	Pharmacy 200 PHARMACY
	Other									-
			/17/2017	Strength F 10MG- 325MG	orm	Quantity 120	Refills	Days Supply 30	Provider , WATSON, MICHAEL JAMES MD	Pharmacy 200 PHARMACY
	Claimer Certain information may not be prescriptions paid for by the pat independently verify medication	ient or non-pa	articipating s							ler should
So	urce Information									
	Source IL PMP (Prescription Monitoring History, Ambulatory)	Program) (Fi		ecked for U 18 9:43 AM				Statu: Histor	s y Response Fi	led

IL PMP alerts prescribers to patients with multiple prescribers, high-dose opioid prescriptions, concomitant opioids and benzodiazapines and daily opioids over 90 days.

Naloxone

Naloxone



Naloxone mechanism of action

- » Highly specific, high-affinity opioid antagonist used to reverse the effects of opioids
- » Lasts 30-90 minutes
- » Can be administered by laypeople
- » Virtually no side effects or effects in the absence of opioids


Providing Naloxone to people who use drugs is cost-effective¹³



Emerging data suggests that providing naloxone may encourage patients to be safer with their opioid use. If this is the case, the intervention would be cost-saving and 36 prescriptions would prevent one death.

Naloxone is effective

Proportion of EMS overdose responses with one or more administration for naloxone



Naloxone administrations per EMS overdose event ¹⁴

EMS patient encounters involving Naloxone per 1,000 EMS encounters 14



Naloxone

Indications for naloxone prescribing

"By being able to offer something concrete [naloxone] to protect patients from the danger of overdose, I am given an opening to discuss the potential harms of opioids in a non-judgmental way."

-Primary care provider

Consider naloxone for patients:

- » With past illicit opioid use
- » At risk of witnessing an opioid overdose

CDC Recommends

On prescribed opioids with:

- » Opioid use ≥50 MMEs/day
- » Benzodiazepine use
- » History of substance use disorder
- » History of opioid overdose
- Other factors that increase overdose risk, including comorbidities or concomitant medications

"I have never really thought about [overdose] before...[naloxone] was more so an eye opener for me to just look at my medications and actually start reading [about] the side effects, you know, and how long should I take them...I look at different options, especially at my age."

-Patient on opioids for pain

State law encourages naloxone prescribing

Naloxone is NOT a controlled substance. Any licensed healthcare prescriber can prescribe naloxone. Illinois law provides additional protections to encourage naloxone prescribing and distribution.

Provider and patient protections

- Providers are encouraged to prescribe naloxone to patients receiving a long-term opioid prescription.
- » Naloxone prescriptions also can be written directly to third party individuals (caregivers, family members, friends, etc.) who are in a position to witness and assist a person at risk of an opioid overdose.
- » A licensed healthcare prescriber can issue a standing order for the dispensing of naloxone by healthcare or community workers to individuals at risk of experiencing or witnessing an overdose.
- » Laypeople can possess and administer naloxone to others during an overdose situation.

Good Samaritan Protections

The Emergency Medical Services Access Law (PA 097-0678, 2012, i.e., Good Samaritan Law), or Illinois' "Good Samaritan Law" allows individuals to seek emergency medical help for an overdose without risking criminal liability for possession.

Pharmacist provision of naloxone

» Pharmacists are allowed to directly prescribe and dispense naloxone to patients at risk of experiencing or witnessing an opioid overdose.

Illinois Laws

- The Illinois Drug Overdose Prevention Program Law (PA 096-0361, 2010) empowers non-medical professionals, including family, friends, and other community members, to administer naloxone to prevent a fatal opioid overdose without risking any civil or criminal liability.
- The Emergency Medical Services Access Law (PA 097-0678, 2012, i.e., Good Samaritan Law), or Illinois' "Good Samaritan Law" allows individuals to seek emergency medical help for an overdose without risking criminal liability for possession.
- The Heroin Crisis Act (PA 099-0480, 2015), also called "Lali's Law," among other things increases access to naloxone, strengthens the Illinois Prescription Monitoring Program (ILPMP), and provides greater access to medication-assisted treatment for opioid use disorder.
- Public Act 100-0564 (2017) mandates that prescribers with controlled substances licenses register with the ILPMP and that they document an attempt to check the ILPMP when providing an initial prescription for opioids (with certain exceptions).

Illinois statewide Naloxone standing order

The statewide Illinois Naloxone Standing Order authorizes trained, licensed pharmacists and overdose education and naloxone distribution (OEND) programs to dispense naloxone to anyone who requests it for the use of reversing a potential opioid overdose, even if they don't have an individual prescription for the medication. The order was issued by the Chief Medical Officer of the Illinois Department of Public Health on September 7, 2017 and will be renewed annually.

Who may obtain and use the Illinois Naloxone Standing Order?

Eligible entities include pharmacies, pharmacists, or opioid overdose education and naloxone distribution (OEND) programs. OEND programs may include law enforcement agencies, drug treatment programs, local health departments, hospitals or urgent care facilities, or other for-profit or not-forprofit community-based organizations that do not have access to a standing order through their organization.

Who should not use the Illinois Naloxone Standing Order?

Individuals should not use the standing order to fill naloxone prescriptions at a pharmacy. Instead, individuals should either obtain a prescription for naloxone from their prescriber, or go to a pharmacy that is using a naloxone standing order.

Naloxone

45%

Opioid safety language

Communicating with patients about naloxone

The word "overdose" may have negative connotations and prescription opioid users may not relate to it.

Some patients have overdosed and don't realize it.

Out of 60 patients on opioid therapy for pain, 22 (37%) had stopped breathing or required help to be woken up due to opioids.¹⁵

of these patients denied overdosing, calling it a bad reaction

Instead of using the word "overdose," consider language like "accidental overdose," "bad reaction" or "opioid safety." You may want to say:

"Opioids can sometimes slow or even stop your breathing." where you can't be woken up."

"Naloxone is for opioid medication like an epinephrine pen is for someone with an allergy." "Naloxone is important to have in the home in case someone is accidentally exposed to opioid painkillers."

Naloxone

Prescribing naloxone

Formulations

Intranasal

» Naloxone 4mg #1 two pack, use PRN for suspected opioid overdose

Auto-Injector

» Naloxone auto-injector 2mg #1 two pack, use PRN for suspected opioid overdose

Devices designed for lay use can cut down on patient education. If the above devices are not optimal, prescriptions can be written for the following formulations and education should be provided directly to the patient.

Intranasal – assembly required

» Naloxone 2mg/2ml prefilled syringe #2, spray 1/2 into each nostril, use PRN for suspected overdose. Repeat if necessary.

Note

Nasal atomizer generally not available through pharmacies

Injectable

» Naloxone 0.4mg IM #2, use PRN for suspected overdose, IM syringe (3ml 25g 1" syringe) #2










Managing opioid use disorder

- » If your patient has an opioid use disorder, it is essential to arrange for treatment.
- » Treatment with medications has the best evidence for managing opioid use disorder and should be considered for all patients with significant disease.
- » When therapy for opioid use disorder is stopped, the risk of death increases.



FDA-approved medication treatment options

- » Buprenorphine (with or without naloxone)
- A list of local community resources can be found in Epic in External Links - Easy Button.

- » Methadone
- » Extended-release naltrexone

Like treatment for other chronic diseases such as diabetes, these medications should be considered long-term therapy.


Behavioral/psychological treatment options

- » Support groups such as Narcotics Anonymous
- » Outpatient or inpatient rehabilitation and counseling

If not personally providing the treatment, a warm handoff to other providers is critical.

For more information regarding additional resources, visit www.dph.illinois.gov/opioids/treatment

Buprenorphine



Buprenorphine

- » A partial opioid agonist
- » Lasts 36 hours
- Has very high affinity, blocking effects of heroin or other opioids


Safety profile

- » Due to the "ceiling effect" of a partial agonist, buprenorphine has:
 - » Low potential for misuse and diversion
 - » Low risk of respiratory depression or overdose
- » Maintenance is critical: opioid use disorder requires long-term care.
- » Buprenorphine treatment is safe and effective during pregnancy.
- » Most buprenorphine for opioid use disorder treatment is co-formulated with naloxone to discourage diversion or injection of the product.

Buprenorphine is an effective medication to treat opioid use disorder in primary care


Routine medication management can be as effective as combining buprenorphine with counseling.

While counseling should be sought if available, lack of access should not be a barrier to treatment.¹⁷



Patients can be started on Buprenorphine in the office or at home.

Opioid use patterns are similar if patients start therapy themselves at home.¹⁸



In a randomized controlled trial of buprenorphine, patients who used only prescription opioids responded even better than those who used heroin (P<0.001).¹⁹

Buprenorphine reduces mortality...

	Methadone CMR (95%CI)	Buprenorphine CMR (95%CI)
First 4 weeks		
All-cause mortality	9.6 (6.5 - 13.5)	4.3 (2.0 - 8.2)
Drug related mortality	5.4 (3.2 - 8.5)	1.0 (0.1 - 3.4)
Remainder of treatment		
All-cause mortality	6.8 (6.3 - 7.4)	3.9 (3.1 - 4.9)
Drug related mortality	1.7 (1.4 - 2.0)	1.5 (1.0 - 2.1)


Buprenorphine reduces mortality, possibly even more than methadone. ²⁰


CMR = Crude Mortality Rate per 1,000 person years

...and pain

Studies support use of bup renorphine for chronic pain. $^{\scriptscriptstyle 21}$

In a study of 35 patients on 200-1,370 morphine equivalent milligrams of opioids for chronic pain, after two months of sub-lingual buprenorphine:





Quality of life scores increased from 6.1 to 7.1 (p=0.005)

Prescribing buprenorphine as maintenance treatment for opioid use disorder requires an "X" number

- An "X" number is a separate DEA registration number that must be used when buprenorphine is prescribed for opioid use disorder.
- » After getting an "X" number, you can prescribe ≤30 patients in year 1 and ≤100 patients in subsequent years.
- » MDs and DOs can apply to treat \leq 275 patients after treating 100 patients for a year.

To obtain an "X" number

If you are a licensed MD or DO:

» Complete a free, 8-hour training (or have substance use disorder treatment experience).
For more information:

www.samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management/qualify-for-physician-waiver-management-qualify-for-physician-gement-qualify-for-physician-gement-qualify-for-physician-gement-qualify-for-physician-gement-qualify-for-physician-gement-qualify-for-physician-gement-gement-qualify-for-physician-geme

» Complete and submit a physician waiver.

If you are a licensed NP or PA:

- » Complete a free, 24-hour training. For more information: www.samhsa.gov/medication-assisted-treatment/quality-nps-pas-waiver
- » Complete and submit a physician waiver.

You will receive a second DEA registration card with your "X" number:

Prescribing buprenorphine ONLY for pain does NOT require an "X" number, but may require prior authorization.

How to prescribe buprenorphine

For opioid use disorder

- » Most patients stabilize between 8-24mg (initial dose is generally 4-8mg).
- » Medication is generally administered sub-lingually and daily.

For pain

- » Any formulation can be used, including the transdermal patch.
- » Prior authorization may be required.
- » No "X" number required.
- » Medication is generally administered 2-3 times daily.

Formulations

Standard for opioid use disorder:

- » Coformulated buprenorphine/naloxone SL tablets.
- » Coformulated buprenorphine/naloxone film or implant.

If patient does not tolerate/cannot access coformulated products:

» Monoformulated buprenorphine SL tablets.

If treating pain, may also consider:

» Monoformulated buprenorphine transdermal patch.

Additional non-pharmaceutical options for patients with chronic pain

Due to increased risk for various complications, patients with an opioid use disorder should also be considered for:

Additional Things to Try to Relieve Pain:

- » Dimming lights
- » Warm blankets
- » Back rub
- » Cold with warm washcloth

Items That May Make You More Comfortable:

- » Ice pack
- » Neck pillow
- » Saline nose spray
- » Warm blanket
- » Extra pillow
- » Mouth swab
- » Warm/Cold compress
- » Warm/Cold washcloth
- » Pillow to raise your knees/ankles
- » Essential Oils

Actions That May Make You More Comfortable:

- » Repositioning
- » Gentle stretching/range of motion
- » Adjust lighting/noise level
- » Walk in the hall
- » Bath or shower
- » Adjust bedding
- » Dietary changes

Additional Options for Relaxation:

- » Ear plugs
- » Personal headphones
- » Quiet/uninterrupted time
- » Eye shield to block light
- » Listen to music
- » Visit from family/friends

Last Updated: 2.2019.



References

- Prescribing Data. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugoverdose/data/prescribing.html. Accessed January 2019
- Hedegaard H, Warner M, Minino A.M. Drug Overdose Deaths in the United States. NHS Data Brief. 2017 Dec; 294. https://www.cdc.gov/ nchs/data/databriefs/db294.pdf. Accessed Jun 2018.
- Drug Overdose Death Data. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugoverdose/data/statedeaths. html. Accessed January 2019.
- Hedegaard H, Warner M, Minino A.M. Drug Overdose Deaths in the United States. NHS Data Brief. 2018 Nov; 329. https://www.cdc.gov/ nchs/data/databriefs/db329-h.pdf
- 5. Illinois Department of Public Health. Prescription Drug Monitoring Program Dashboard. https://idph.illinois.gov/OpioidDataDashboard/. Accessed June 2018.
- Darke S, Williamson A, Ross J, Teesson M. Non-fatal heroin overdose, treatment exposure and client characteristics: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005 Sept;24 (4):425-32.
- Policy Impact: Prescription Painkiller Overdoses. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugoverdose/pdf/PolicyImpact-PrescriptionPainkillerOD-a.pdf Updated 2013. Accessed August 2019.
- 8. Southern Illinois Healthcare. Rehabilitation Institute of Chicago.
- Smith P, Schmidt S, Allensworth-Davies D, Saitz R. A Single-Question Screening Test for Drug Use in Primary Care. Arch Intern Med. 2010 Jul; 170(13): 1155–1160.
- Martin B, Fan M, Devries A, Braden J, Sullivan M. Long-Term Chronic Opioid Therapy Discontinuation Rates from the TROUP Study. J General Intern Med. 2011 Dec;26(12):1450-7.
- Prescription Drug Monitoring Program Center of Excellence. COE Briefing: PDMP Prescriber Use Mandates: Characteristics, Current Status, and Outcomes in Selected States. 2016. Waltham, MA: Brandeis University. https://www.pdmpassist.org/pdf/Resources/ Briefing_on_mandates_3rd_revision_A.pdf Accessed August 2019.
- Pardo B. Do More Robust Prescription Drug Monitoring Programs Reduce Prescription Opioid Overdose? Addiction. 2017. doi: 10.1111/add.13741.

- Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. http://prescribetoprevent. org/wp-content/uploads/Coffin_Cost-effectiveness-article.pdf Accessed August 2019
- Illinois Department of Public Health.Opioid Overdose Semiannual Report- June 2018. http://www.dph.illinois.gov/sites/default/ files/publications/publicationsoppsopioid-semiannual-report-june2018.pdf
- Behar E, Rowe C, Santos GM, Murphy S, Coffin PO. Primary Care Experience with Naloxone Prescription. Ann Fam Med. 2016;14(5)431-436.
- Pierce M, Bird S, Hickman M, Marsden J, Dunn G, Jones A, Millar T. Impact of treatment for opioid dependence on fatal drug related poisoning: a national cohort study in England. Addiction. 2016 Feb;111(2):298-308.
- Weiss RD, Potter J, Fiellin D, Bryne M, Connery H, Dickinson W, et al. Adjunct counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011 Dec;68(12):1238-46.
- Cunningham CO, Giovanniello A, Li X, Kunins H, Roose R, Sohler N. A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office based inductions. J Subst Abuse Treat. 2011 Jun;40(4):349-56.
- Nielsen S, Hillhouse M, Thomas C, Hasson A, Ling W. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. J Addict Med. 2013;7(1):33-8.
- Kimber J, Larney S, Hickman M, Randall D, Degenhardt L. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet. 2015;2(10):901-908.
- Daitch D, Daitch J, Novinson D, Frey M, Mitnick C, Pergolizzi J Jr. Conversion from High-Dose Full-Opioid Agonists to Sublingual Buprenorphine Reduces Pain Scores and Improves Quality of Life for Chronic Pain Patients. Pain Med. 2014;15(12):2087–2094.

Opioid Stewardship and Chronic Pain

A special thank you to the San Francisco Department of Public Health for allowing us to update their "Opioid Stewardship and Chronic Pain: A Guide for Primary Care Providers. San Francisco, CA. October 2017" for use in Illinois.

This project was supported wholly or in part through a State Opioid Response (SOR) grant to the Illinois Department of Human Services, Division of Substance Use Prevention and Recovery from the U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (TI-081699).

The recommendations contained in this guide are general and informational only; specific clinical decisions should be made by providers on an individual case basis.

02.2020